UBS AG lowered shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) from an outperform rating to a market perform rating in a research note released on Thursday morning, The Fly reports.

Several other research analysts have also commented on TEVA. Jefferies Group LLC reiterated a hold rating on shares of Teva Pharmaceutical Industries Limited in a research note on Tuesday, July 25th. Maxim Group reiterated a hold rating and set a $35.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, July 13th. Mizuho reiterated a hold rating and set a $30.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday. Credit Suisse Group set a $39.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the stock a buy rating in a research note on Thursday. Finally, BTIG Research reiterated a neutral rating on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, April 6th. One equities research analyst has rated the stock with a sell rating, twenty-two have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Teva Pharmaceutical Industries Limited currently has a consensus rating of Hold and a consensus price target of $39.81.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down 13.26% during midday trading on Thursday, hitting $20.60. 93,317,085 shares of the stock were exchanged. The company has a market cap of $20.93 billion, a PE ratio of 264.10 and a beta of 0.46. The firm’s 50 day moving average price is $32.05 and its 200 day moving average price is $32.28. Teva Pharmaceutical Industries Limited has a 12 month low of $20.41 and a 12 month high of $55.45. Teva Pharmaceutical Industries Limited also was the recipient of unusually large options trading activity on Thursday. Traders bought 66,716 put options on the stock. This represents an increase of approximately 864% compared to the typical volume of 6,922 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.06 by $0.07. The firm had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.18% and a negative net margin of 25.18%. The company’s revenue was up 12.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.25 EPS. On average, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post $4.65 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/08/06/teva-pharmaceutical-industries-limited-nyseteva-rating-lowered-to-market-perform-at-ubs-ag.html.

Several institutional investors have recently bought and sold shares of the stock. Cribstone Capital Management LLC boosted its position in Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock valued at $101,000 after buying an additional 100 shares in the last quarter. Bronfman E.L. Rothschild L.P. boosted its position in Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after buying an additional 261 shares in the last quarter. Kistler Tiffany Companies LLC boosted its position in Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after buying an additional 1,571 shares in the last quarter. FNY Managed Accounts LLC purchased a new position in Teva Pharmaceutical Industries Limited during the first quarter valued at about $123,000. Finally, Sterling Investment Advisors Ltd. boosted its position in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after buying an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 56.20% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

The Fly

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.